Breaking News


Effects of 12-week ustekinumab and etanercept therapy in psoriasis


Serum proteins and subsets of inflammatory markers were examined as proxy markers of psoriatic activity in 145 patients who had received 12 weeks of etanercept or ustekinumab for moderate-severe psoriasis. No consistent changes in normalized serum protein profiles were seen based on treatment response at weeks 4 or 12 across either group. However, IL-8, C-reactive protein (CRP) and CCL4 levels were significantly decreased in patients on etanercept. Serum CCL4 was minimally affected by ustekinumab and trends toward decreases in IL-8 and CRP were seen. Median numbers of circulating lymphocytes were unchanged across groups; no significant changes in CD4+ T-cells, CD8+ T-cells, regulatory T-cells, CLA+ cells, natural killer T-cells or cytokine production in ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list